Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03745989 · ClinicalTrials.gov registry record · Phase 1
Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03745989 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 30 participants.
The verdict
NCT03745989, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a multicenter, worldwide, open-label study of MK-8353 in combination with selumetinib in participants with histologically or cytologically confirmed diagnosis of advanced solid tumor. This study will evaluate the safety, tolerability, and exploratory efficacy of MK-8353 in combination with selumetinib.
Interventions
- DRUG Selumetinib
- DRUG MK-8353
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-02-22 |
| Est. Completion | 2021-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03745989
The ClinicalTrials.gov registry entry for NCT03745989 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Selumetinib is the first listed.
NCT03745989 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03745989 about?
NCT03745989 is a clinical study titled "Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)". This is a multicenter, worldwide, open-label study of MK-8353 in combination with selumetinib in participants with histologically or cytologically confirmed diagnosis of advanced solid tumor. This study will evaluate the safety, tolerability, and exploratory efficacy of MK-8353 in combination with s...
What is the current status of trial NCT03745989?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-02-22. Estimated completion is 2021-03-19.
What interventions are being tested in trial NCT03745989?
The interventions under investigation include: Selumetinib (DRUG), MK-8353 (DRUG).
Who is sponsoring clinical trial NCT03745989?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.